2029, Immunization and Labelling

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Immunization

Labelling

Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData

Express Pharma

FEBRUARY 21, 2024

billion by 2029. “ There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). billion in 2023, and GlobalData projects it to surpass $14 billion by 2029.

Chemotherapy

Chemotherapy Labelling Immunity Immunization

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

JUNE 16, 2025

At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 June 12 to 15 June in Milan, Italy, preliminary dose-escalation and optimisation results from the global, multicentre, open-label, single-arm Phase I/II SYRUS clinical trial (NCT06137118) were presented on the second day.

Labelling

Labelling Communication Hospitals Vaccines

Pharmacist Digest

Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Stay Connected